α-Bisabolol and its derivatives are potential cancer treatment drugs which have anti-cancer activity through inhibiting the serine/threonine kinase (Brehm-Stecher and Johnson 2003; Kim et al. 2011; Murata et al. 2017; Seki et al. 2011). The gene discussed is MARK2; the disease is cancer.